Natalizumab (Nz), a monoclonal antibody has been in medicinal use for the treatment of relapsing-remitting multiple sclerosis (RRMS) since 2004 .
Haematological complications which are associated with its long-term use have been reported [2,3,4]. Animal studies have shown conflicting evidence of some reporting haematological complications [5,6,7,8], though some did not show such an observation .
Reversible hyporegenerative anaemia secondary to Natalizumab has been described , but associated leucopenia to the best of our knowledge is not described in the literature.
Our case highlights the risk of non-immune-mediated reversible hyporegenerative anaemia co-occurring with leucopenia and lymphopenia which to date has not been reported.
We report a case of a 21-year old student with relapsing-remitting multiple sclerosis (RRMS). He was diagnosed at the age of 12 years and was on Natalizumab.
Past disease-modifying treatment included injection interferon beta 1a 44 mcg subcutaneous 3 times/week for 4 years. This was switched to Natalizumab 5 years ago in 2014 due to high disease activity.
Since being on Natalizumab, he achieved disease remission. However, it was first noticed that his haemoglobin and white cells count were decreasing in November 2018 which prompted further investigations.
Baseline haemoglobin between July 2016 and 2017 was between 14 and 16 g/dL—which dropped sequentially to ranges from 8 to 10 g/dL from 2018 to 2019, as shown in Fig. 1.
The white cell count also dropped during the same period he was on Natalizumab from 6.5 to 1.42 × 109/L. Lymphocyte count progressively dropped to 0.11 × 109/L. Trends are shown in Figs. 2 and 3 respectively.
The platelet counts stayed stable throughout the time period. He was investigated extensively for this drop in his blood lines and the notable abnormalities were evidence of non-immune haemolysis, splenomegaly and hyperbilirubinemia.
The rest of his haematological parameters are shown in Table 1.
Bone marrow aspirate and trephine showed erythrodysplasia. Genetic panel and karyotyping were negative for acquired genetic changes for myelodysplasia.
Genetic panel also included inherited bone marrow failure disorders (congenital dyserythroblastic anaemia, congenital bone marrow failure, Diamond-Blackfan anaemia) which were negative. Blood lymphocyte subset analysis revealed preserved B-cells and depletion of T and NK cells.
Non-immune hemolysis has been confirmed by repeatedly negative direct Coombs test (DCT), raised LDH, absent haptoglobin and raised bilirubin, notably urinary hemosiderin was negative with a poor reticulocyte response despite anaemia. Pertinent negative investigations included screening for haemoglobinopathies, paroxysmal nocturnal haemoglobinuria, G6PD deficiency, and parvovirus B19 infections.
Natalizumab was stopped in November 2018 after a total of 44 infusions. His blood lines started showing improvements which were suggestive of Natalizumab-associated reversible hyporegenerative anaemia with leucopenia. Due to a sensory relapse in March 2019, he has been started on glatiramer acetate 40 mg S/C injection via Autoject device 3 days/week which he is tolerating well, and his cell counts are improving.